$-0.10 EPS Expected for Anavex Life Sciences Corp. (AVXL) on May, 9

April 17, 2018 - By Eula Gilbert

Anavex Life Sciences Corp. (NASDAQ:AVXL) Corporate Logo

On May, 9. Investors wait Anavex Life Sciences Corp. (NASDAQ:AVXL) to report its quarterly earnings, RTT reports. The earnings per share diference is $0.01 or 11.11 % down from last years number. Previous year: $-0.09; Analysts forcast: $-0.10. 11.11 % negative EPS growth is what Wall Street’s forecasts after $-0.09 reported EPS last quarter. Its shares touched $2.23 on during the last trading session after 3.72% change.Currently Anavex Life Sciences Corp. is downtrending after 55.59% change in last April 17, 2017. AVXL has 200,258 shares volume. The stock underperformed the S&P 500 by 67.14%.

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer??s disease, other central nervous system diseases, pain, and various cancers.The firm is worth $99.40 million. The company??s lead drug candidates include ANAVEX 2-73, which has completed Phase IIa clinical trials for the treatment of Alzheimer??s disease; and in preclinical clinical trials to treat Parkinson??s disease, epilepsy, Rett syndrome, Angelman syndrome, multiple sclerosis, and Fragile X syndrome.Currently it has negative earnings. The Company’s preclinical drug candidates include ANAVEX 3-71 to treat Alzheimer??s disease; ANAVEX 1-41, a sigma-1 agonist; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain.

Anavex Life Sciences Corp. (NASDAQ:AVXL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.